✦ LIBER ✦

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

✍ Scribed by Ronald P DeMatteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter WT Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar

Book ID: 117304545
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 197 KB
Volume: 373
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(09)60500-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9413 Phase II trial of adjuvant imatinib

9413 Phase II trial of adjuvant imatinib mesylate after resection of localized, primary high risk gastrointestinal stromal tumour (GIST) in Japan

✍ Nishida, T.; Kanda, T.; Wada, N.; Kobayashi, O.; Yamamoto, M.; Sawaki, A.; Boku, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Efficacy and safety of sunitinib in pati

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

✍ George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackste 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 201 KB

Efficacy and safety of regorafenib for a

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

✍ Demetri, George D; Reichardt, Peter; Kang, Yoon-Koo; Blay, Jean-Yves; Rutkowski, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 348 KB